Xenon Pharmaceuticals Inc. (XENE) |
|
35.38 0.35 (1%)
|
09-27 11:35 |
|
Open: |
35.13 |
Pre. Close: |
35.03 |
|
High:
|
35.545 |
Low:
|
34.97 |
|
Volume:
|
84,810 |
Market Cap:
|
2,269(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 11:20:51 AM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 44.45 One year: 46.87 |
| Support: |
Support1: 34.7 Support2: 28.87 |
| Resistance: |
Resistance1: 38.05 Resistance2: 40.13 |
| Pivot: |
36.52  |
| Moving Average: |
MA(5): 35.3 MA(20): 37.19
MA(100): 38.8 MA(250): 37.63 |
| MACD: |
MACD(12,26): -0.8 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 9.4 %D(3): 9.2 |
| RSI: |
RSI(14): 34 |
| 52-week: |
High: 43.75 Low: 31.79 |
| Average Vol(K): |
3-Month: 320 (K) 10-Days: 353 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XENE ] has closed above bottom band by 20.0%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
35.94 - 36.14 |
36.14 - 36.3 |
|
Low:
|
34.09 - 34.37 |
34.37 - 34.6 |
|
Close:
|
34.62 - 35.03 |
35.03 - 35.37 |
|
Company Description |
|
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. |
Headline News |
Mon, 25 Sep 2023
DNB Asset Management AS Has $4.34 Million Holdings in Xenon ... - MarketBeat
Fri, 22 Sep 2023
RBC Capital Reiterates Xenon Pharmaceuticals (XENE) Outperform ... - Nasdaq
Sat, 16 Sep 2023
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews ... - MarketBeat
Tue, 12 Sep 2023
Xenon Pharmaceuticals Announces Upcoming Investor Webinar ... - GlobeNewswire
Wed, 30 Aug 2023
Oppenheimer & Co. Inc. Invests $451000 in Xenon Pharmaceuticals ... - MarketBeat
Wed, 09 Aug 2023
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
64 (M) |
|
% Held by Insiders
|
5.901e+007 (%) |
|
% Held by Institutions
|
0.6 (%) |
|
Shares Short
|
2,650 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.843e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-141 |
|
Return on Assets (ttm)
|
10.6 |
|
Return on Equity (ttm)
|
-15.6 |
|
Qtrly Rev. Growth
|
132000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-17.06 |
|
EBITDA (p.s.)
|
-7.18881e+007 |
|
Qtrly Earnings Growth
|
-2.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-131 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-2.07 |
|
Price to Cash Flow
|
4.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.78e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
